What’s Ahead for Jaguar Animal Health Inc (JAGX) After Forming Bearish Double Bottom Pattern?

July 18, 2017 - By Marie Mckinney

The chart of Jaguar Animal Health Inc (JAGX) shows a double bottom with $0.64 target or 9.00 % below today’s $0.70 share price. The 5 months chart pattern indicates high risk for the $12.29 million company. It was reported on Jul, 18 by Finviz.com. If the $0.64 price target is reached, the company will be worth $1.11M less. Double bottoms are rare but powerful chart patterns.

The stock increased 2.94% or $0.02 on July 17, reaching $0.7. About shares traded. Jaguar Animal Health Inc (NASDAQ:JAGX) has declined 48.63% since July 18, 2016 and is downtrending. It has underperformed by 65.33% the S&P500.

Jaguar Animal Health Inc (NASDAQ:JAGX) Ratings Coverage

Among 2 analysts covering Jaguar Animal Health (NASDAQ:JAGX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Jaguar Animal Health had 2 analyst reports since July 11, 2017 according to SRatingsIntel. The stock of Jaguar Animal Health Inc (NASDAQ:JAGX) earned “Buy” rating by H.C. Wainwright on Tuesday, July 11.

More notable recent Jaguar Animal Health Inc (NASDAQ:JAGX) news were published by: Businesswire.com which released: “Jaguar Animal Health and Napo Pharmaceuticals Announce Filing of Two Orphan …” on June 05, 2017, also Businesswire.com with their article: “Jaguar Animal Health and Napo Pharmaceuticals Appoint Dr. Pravin Chaturvedi to …” published on May 10, 2017, Businesswire.com published: “Jaguar Animal Health Launches Commercial Website for Neonorm Foal & Neonorm Calf” on June 07, 2017. More interesting news about Jaguar Animal Health Inc (NASDAQ:JAGX) were released by: Businesswire.com and their article: “Lisa Conte, CEO of Jaguar Animal Health and Napo Pharmaceuticals, to Present …” published on May 25, 2017 as well as Finance.Yahoo.com‘s news article titled: “Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger Agreement” with publication date: March 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.